English
FrançaisAbstract Track Descriptors
Track Descriptors
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Track Descriptors
Description: This track will encompass all aspects of fundamental HIV biology and the host response to HIV. Areas of focus will include HIV infection and replication, transmission, genetics, evolution, structure and function, pathogenesis, adaptive and innate immune responses to HIV, genetic susceptibility to HIV, interaction of micronutrients, co -infection and progress in animal models. Pre-clinical vaccine, microbicide, and drug development will be important themes of this track.
Abstract Categories
HIV EVOLUTION, VIRAL DIVERSITY AND BIOINFORMATICS
A1. HIV-1/2: Origins, evolution, diversity and response to ARV
A2. Molecular epidemiology of HIV diversity
A3. Bioinformatics analysis of HIV diversity and drug resistance
IMMUNOLOGY OF HIV
A4. Innate immune responses and function in natural history of HIV infection
A5. Humoral immune responses and function in natural history of HIV infection
A6. Cellular immune responses and function in natural history of HIV infection
A7. Immune responses in resistant cohorts: elite controllers and exposed uninfected
TRANSMISSION AND PATHOGENESIS (HIV-1/2)
A8. Viral determinants of HIV pathogenesis
A9. Acute and early HIV infection
A10. Animal models of transmission, disease resistance and progression
A11. HIV transmission (mucosal and mother to child transmission; other transmission)
A12. Ageing and HIV
Host genetics and HIV infections
A13. Host genetics of resistance and susceptibility and restriction factors
HIV: Co-infections and emerging pathogens
A14. HIV super-infection
A15. HIV co-infection with TB and other pathogens (Hepatitis B, C, HPV, bacterial agents..)
A16. HIV interactions with emerging and other opportunistic pathogens
A17. HIV and host Microbiota
HIV: Drug development and resistance
A18. HIV drug development: Synthetic, traditional and microbicides
A19. Molecular mechanisms of drug action and antiviral drug resistance and drug interaction
A20. Nucleic acid based HIV and SIV therapies
A21. Targeting and HIV persistence during ART (cure strategies)
Vaccine development
A22. Clinical trials in HIV vaccine development
A23. Animal models for vaccine development
Interaction of micronutrients and HIV infection
A24. Effect of micronutrients in HIV and AIDS pathogenesis, transmission and treatment
A25. Mechanisms of micronutrient and HIV interactions
Diagnostics tools development (for use in resource limited settings)
A26. Novel assays of immune responses in HIV and AIDS
A27. Novel assays and cost effectiveness tools for virological monitoring
A28. Rapid and cost-effective HIV screening and diagnostic methods
A29. HIV drug resistance testing
Characterization of HIV latency and viral reservoirs
A30. Measurement of HIV/SIV reservoirs
A31. Host cellular latency
A32. Targeting and eradication of reservoirs
COVID 19
A33. Basic science, pathogenesis, virology, immunology, inflammation
A34. Covid-19 Vaccine
A35. COVID-19 Molecular testing and algorithm
A36. COVID-19 testing RTD and Ag testing
A37. COVID-19 genetic diversity
Description: This track will encompass all aspects of fundamental HIV biology and the host response to HIV. Areas of focus will include HIV infection and replication, transmission, genetics, evolution, structure and function, pathogenesis, adaptive and innate immune responses to HIV, genetic susceptibility to HIV, interaction of micronutrients, co -infection and progress in animal models. Pre-clinical vaccine, microbicide, and drug development will be important themes of this track.
Abstract Categories
Clinical course of HIV infection and disease
B1. Natural history of HIV Disease including markers of HIV Disease progression
B2. Pre-ART Patient Care: Opportunities and Challenges
B3. Morbidity and mortality/life expectancy during ART
B4. Acute and early HIV infection, meeting the new targets (95-95-95)
Diagnosis and management of co-infections/co-morbidities
B5. Co-infections (TB, Hepatitis, STIs, Cryptococcus, bacterial diseases, leishmaniosis, Malaria and others)
B6. Prophylaxis against common opportunistic infections (CPT, IPT, antifungal)
B7. immunization in HIV infected people
B8. Diagnosis and management of Hepatitis B/C
B9. Tools for diagnosis and management of infections: point of care
B10. Diagnosis and management of STIs
B11. Syphilis, HPV and others
HIV and NCDS
B12. Diabetes, cardiovascular, renal diseases, bone mineral diseases, HIV and neurocognitive disorders)
B13. HIV and malignancies
B14. HIV, Ageing and Fragility
Antiretroviral therapy
B15. First line therapy (when to start, what to start with, durability) Differentiated HIV Care
B16. ART monitoring strategies
B17. Treatment failure: drug resistance, second line therapy and salvage therapy
B18. Adherence and retention
B19. Antiretroviral therapy in children
B20. Antiretroviral therapy in adolescents
B21. Antiretroviral therapy and PMTCT in pregnant women
B22 Antiretroviral therapy in elder populations
B23. Adverse effects of antiretroviral therapy including immune reconstitution syndrome be sure Track C integrate this (quality of life…)
B24. HIV-2, HIV-1+2 infections
B25 Management of HIV infection in Key Populations
B26. Cost effectiveness of ART
B27. Antiretroviral therapy to prevent HIV-Transmission
B28 ART maintenance simplification
Palliative care and nutrition
B29. Pain management and end of life care
B30. Clinical nutritional care in HIV infection
B31. Home and community based care and support
B32. Other Strategies and Therapies (traditional medicine, spiritual care)
Clinical guidelines, tools and algorithms
B33. Country adaptation of global HIV diagnosis and treatment guidelines
B34. Diagnosis and monitoring tools
COVID 19
B35. Clinical science, testing (RT –PCR and serologic)
B36. COVID 19 Impact on HIV related services
B37. Innovation in Service delivery approaches
Description: This track will focus on HIV and AIDS prevention research and issues related to the design, implementation and evaluation of prevention programs to reach the SDG. It will include examination of Research, methodological and programmatic advances in the continuum of prevention, particularly best practices in HIV prevention for vulnerable populations in resource-limited settings. Strategies to put HIV prevention research into practice, efforts to promote preparedness for bio-medical prevention technologies, and research on new prevention approaches including microbicides, vaccines, pre- and post-exposure prophylaxis, circumcision and other methods will be presented. This Track will also address co-morbidities (Hepatitis, Tuberculosis, and STI’s, communicable end emerging diseases) and emerging.
Abstract Categories
Basic HIV Epidemiology
C1. Natural history of HIV
C2. HIV prevalence and incidence trends, morbidity and mortality trends
C3. Epidemiology in general population, risk factors for acquisition of HIV, including sero discordant couples
C4. Risk factors for acquisition of HIV, geographic heterogeneity and contextual
C5. Epidemiology of HIV in the aged (50+)
C6. Epidemiology of HIV in youth, adolescents and children
Epidemiology of HIV co‐morbidity and emerging diseases
C7. HIV and other sexually transmitted infections (STI)
C8. HIV and Tuberculosis co‐infection
C9. HIV and Malaria co‐infection
C10. HIV and Viral hepatitis co-infection
C11. HIV and non‐communicable diseases (cardiovascular risk, metabolic diseases, mental health, reproductive health, etc.)
C12. HPV infections and cancers in people living with HIV
C13. HIV infection in Africa and cancers associated with human papillomavirus (anus; cervix; throat), other associated cancers
C14. HIV, Opportunistic Infections (OI) and the epidemiology of emerging diseases
C15. Quality of life of people living with HIV
Social Epidemiology of HIV
C16. Sexual behavior, vulnerability and Most at Risk Populations (MARPS)including adolescent girls and young women
C17. Socio‐cultural and economic determinants of HIV
C18. Relapse of risky behaviors with the advent of ART
C19. Gender based violence and HIV transmission
HIV/AIDS Surveillance and Monitoring and Evaluation
C20. Modeling HIV epidemic in the advent of ART, where does M and E fit?
C21. HIV and AIDS Surveillance:Routine,Sentinel,Second generation and HIV phylogenetics
C22. Surveillance of opportunistic infections
C23. Surrogate markers: What remains of the measurement of CD4 T lymphocytes in a situation of accessibility of the viral load?
Surveillance of HIV Drug resistance
C24. Population‐based HIV sero epidemiologic studies, and measuring new HIV infections, including in children
C25. HIV reservoir: "deep" residual infectivity in HIV reservoirs in people correctly treated according to the algorithms proposed by the WHO
Methodological Issues and Capacity‐Building in Epidemiological and Prevention Research
C26. Novel Research, Ethical and human rights issues in epidemiological and prevention research
C27. Measuring and modelling the impact of prevention and treatment interventions on the HIV epidemic at the population level.
C28. Methods aimed at measuring the impact of the HIV epidemic, recent HIV infections and HIV incidence
C29. Surveillance systems and methods including geographical information system
C30. Estimation of the size of KP
HIV/AIDS Prevention Programmes
C31. Triple Elimination of Prevention of Mother to Child Transmission of HIV, Hepatitis B and syphilis
C32. Prevention programmes in institutional and community settings
C33. Prevention programmes for immigrants, mobile and displaced populations
C34. Integrated prevention for and with PLHIV, and key populations
C35. Integrated HIV prevention for adolescents and young people
C36. Therapeutic and psychosocial care for adolescents and young adults born to infected mothers;
C37. HIV Prevention technologies
C38. New approaches for HIV prevention
C39. Integrating HIV prevention into reproductive health, care, support and treatment programmes
C40. HIV Testing and diagnosis strategies
Diversified prevention tools
C41. PeP
C42. PrEP
C43. Microbicides
C44. Ehealth
C45. VMMC
COVID 19
C46. Epidemiology, transmission dynamics, prevention, vaccines
C47. HIV Infection and COVID-19
C48. Impact of COVID-19 on HIV response
Description: This track aims to highlight new knowledge and address gaps in the translation of behavioral and social science evidence into practice, and to contribute to the building of theory and understanding in HIV-related social science. The track also aims to promote understanding of the individual and social determinants of HIV-related risk, vulnerability and impact, to inform development of effective and sustainable HIV responses that are based on human dignity and individual entitlements. This track will feature research, analysis and evaluation on psychosocial factors that shape individual attitudes, experiences, and behaviors; social and structural factors that shape vulnerability and risk; social and cultural norms that underlie individual risk and community vulnerability; programmes that promote acceptation of human diversity and fast track access to HIV and STI prevention, treatment, care and support; social and structural factors that shape vulnerability; and methods and outcomes of individual and community engagement, leadership, empowerment, and self-determination. In addition, this track will examine evidence underpinning HIV related stigma, discrimination and exclusion, lessons emerging from the practice of restoring dignity and coping capacities of those affected.
Abstract Categories
Human rights, law and ethics
D1. Laws, protection and empowerment of PLHIV and vulnerable populations
D2. Human right, Protections and HIV services for Key and vulnerable populations
D3. Human rights, ethics and use of antiretroviral drugs for treatment and prevention
D4. Children’s rights, protections and HIV
D5. Human Rights, Sexual rights and access to citizenship
D6. Human rights, Ethics HIV testing, policy and practice
D7. Human rights, culture religion, social, behavior, culture and harm reduction
D8. Ethics, law and research
D9. Clinical services, public health policy and programmes
D10. Ethics, human right, access to medicines for prevention, treatment and care
Stigma, Discrimination and the Legal Environment
D11. Experience and impacts of HIV and TB related stigma
D12. Intersecting stigmas, marginalized identities, Homophobia and transphobia
D13. Racism, ethnicity-based social exclusion and HIV control
D14. Stigma, discrimination, key and vulnerable populations affected by HIV
D15. Stigma, social attitudes, media and public debate
D16. Punitive laws, enforcement and HIV risk
SEX, SEXUALITY, GENDER AND MEDIA REPORTING IN HIV
D17. Gender equality, power dynamics and gender equity: Addressing a feminized epidemic
D18. Sexualities and sexual cultures
D19. Adolescents, young people, and HIV
D20. same – sex- attracted, bisexual and queer people
D21. Feminity, masculinity and transgender issues in HIV
D22. Relationships, partnership, concurrency and sexual networks
D23. New prevention technologies and Family-centered approach to HIV care and support
D24. HIV Co-morbidities
Policies, Programs and HIV response
D25. Policy, politics and HIV management
D26. Law enforcement and vulnerable populations
D27. Harassment and Discrimination
D28. Harm reduction policies and politics
D29. Access to HIV management
D30. Health and HIV Policy development, implementation and evaluation
D31. Policies for HIV prevention, diagnosis, treatment, care, protection and support
D32. Policies and socio-economic determinants of vulnerability
D33. HIV policies, the workplace, and educational institutions
D34. HIV policies and intellectual property, treatment access and TRIPS
D35. Policy M&E, analysis, impact and indicators of policy effectiveness
D36. Evidence–informed advocacy for policy formulation and review
Social theories and knowledge production
D37. HIV prevention theories and approaches
D38. Social, cultural and behavioral science collaboration
D39. Methods in social and behaviour surveys
Communication, mass media and popular education
D40. Communication strategies on HIV and AIDS
D41. The media and HIV and AIDS
D42. Digital media, social networking and HIV prevention, treatment, care and support
D43. HIV, media, culture and religion
D44. Media and policy making
D45. Inter- organizational communication and knowledge transfer
D46. Intergenerational communication and HIV
Socio-cultural determinants of HIV
D47. Family structures, kinship and social security networks among key and vulnerable populations
D48. Harmful traditional practices and HIV
D49. Youth, globalization and HIV
D50. Sex work, the global recession and HIV
D51. Traditional and complementary approaches in the response to HIV
STRUCTURAL DETERMINANTS OF HIV
D52. Poverty, social and socio-economic structures and HIV
D53. Fertility, family planning, Reproductive rights, health and HIV
D54. Family-centered approach to HIV care and support
D55. Conceptualizing social and structural factors and their impacts
D56. Poverty, wealth. Income inequalities and HIV
D57. Dynamics of social status and power
D58. Gender, age, ethnicity, disability and HIV
D59. Economic transitions, socio-cultural changes and HIV risk
D60. Social dynamics, intergenerational differences and HIV
D61. Migrants, migration and population dislocation
D62. Fertility, family planning, reproductive health services and HIV
D63. Violence, conflict and HIV
D64. Humanitarian disasters and HIV
D65. Gender based violence and HIV
D66. Prisons, closed settings and HIV
COVID 19
D67. Public Health responses including physical distancing and community level effort, programme policies, lifting restrictions, modelling.
D68. Intersections between Covid19 and HIV
D69. Impact of Covid-19 on HIV Mental Health
D70. Innovative approaches by communities to respond to human rights violations in the context of HIV
D71. Innovative approaches by communities to respond to HIV in a context of COVID 19
Description: This track will aim to provide new insights into the status of the health systems and its capacity and challenges to expanding treatment and prevention in resource-limited settings. At the same time, issues related to health economics, integration of health programs, country ownership of national health and HIV programs, and advancement of a comprehensive and integrated approach to health and rights will be discussed. This Track must show the need for a holistic vision of the fight against the disease by the effective strengthening of health systems. The verticalization of the fight is not a proper and appropriate response in a context where we have recurrent epidemics.
Abstract Categories
HIV and health system strengthening
E1. AIDS investments for health system strengthening
E2. Innovative responses to resource needs for health system strengthening
E3. Procurement and supply chain management
E4. Community systems strengthening for health care delivery
E5. Public health systems and the delivery of HIV care at scale
Management for health care delivery
E6. Gender responsive HIV programming
E7. Integrated HIV service delivery services with non-health response programs
E8. Decentralization, differentiated care and task-shifting
SHARED RESPONSIBILITY, GLOBAL SOLIDARITY AND THE SDGS
E9. Governance – peer review and accountability mechanisms
E10. Sustainable financing options and financial tracking
E11. Accelerated access to medicines, vaccines, and diagnostics
E12. Capacity strengthening for HIV domestic program funding.
Health economics
E13. Building country-level capacity for quality improvement
E14. Evaluation of integrated models of health service delivery
E15. Health access financing models for HIV service delivery
Partnership in HIV
E16. Private-public partnership and HIV care delivery
E17. Innovative partnership models
Innovation and best practices
E18.Interventions for increase uptake of and retention in HIV services
E19. Public-private partnerships
E20. Technologies for HIV care delivery
COVID 19
E21. Social, Economic, Political, Human right impact of the pandemic and the response.
E22. Integrated HIV and COVID 19 care
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien. Praesent id enim sit amet odio vulputate eleifend in in tortor. Donec tellus massa, tristique sit amet condim vel, facilisis quis sapien.
Description: This track will encompass all aspects of fundamental HIV biology and the host response to HIV. Areas of focus will include HIV infection and replication, transmission, genetics, evolution, structure and function, pathogenesis, adaptive and innate immune responses to HIV, genetic susceptibility to HIV, interaction of micronutrients, co -infection and progress in animal models. Pre-clinical vaccine, microbicide, and drug development will be important themes of this track.
Abstract Categories
| HIV EVOLUTION, VIRAL DIVERSITY AND BIOINFORMATICS |
| A1. HIV-1/2: Origins, evolution, diversity and response to ARV |
| A2. Molecular epidemiology of HIV diversity |
| A3. Bioinformatics analysis of HIV diversity and drug resistance |
| IMMUNOLOGY OF HIV |
| A4. Innate immune responses and function in natural history of HIV infection |
| A5. Humoral immune responses and function in natural history of HIV infection |
| A6. Cellular immune responses and function in natural history of HIV infection |
| A7. Immune responses in resistant cohorts: elite controllers and exposed uninfected |
| TRANSMISSION AND PATHOGENESIS (HIV-1/2) |
| A8. Viral determinants of HIV pathogenesis |
| A9. Acute and early HIV infection |
| A10. Animal models of transmission, disease resistance and progression |
| A11. HIV transmission (mucosal and mother to child transmission; other transmission) |
| A12. Ageing and HIV |
| Host genetics and HIV infections |
| A13. Host genetics of resistance and susceptibility and restriction factors |
| HIV: Co-infections and emerging pathogens |
| A14. HIV super-infection |
| A15. HIV co-infection with TB and other pathogens (Hepatitis B, C, HPV, bacterial agents..) |
| A16. HIV interactions with emerging and other opportunistic pathogens |
| A17. HIV and host Microbiota |
| HIV: Drug development and resistance |
| A18. HIV drug development: Synthetic, traditional and microbicides |
| A19. Molecular mechanisms of drug action and antiviral drug resistance and drug interaction |
| A20. Nucleic acid based HIV and SIV therapies |
| A21. Targeting and HIV persistence during ART (cure strategies) |
| Vaccine development |
| A22. Clinical trials in HIV vaccine development |
| A23. Animal models for vaccine development |
| Interaction of micronutrients and HIV infection |
| A24. Effect of micronutrients in HIV and AIDS pathogenesis, transmission and treatment |
| A25. Mechanisms of micronutrient and HIV interactions |
| Diagnostics tools development (for use in resource limited settings) |
| A26. Novel assays of immune responses in HIV and AIDS |
| A27. Novel assays and cost effectiveness tools for virological monitoring |
| A28. Rapid and cost-effective HIV screening and diagnostic methods |
| A29. HIV drug resistance testing |
| Characterization of HIV latency and viral reservoirs |
| A30. Measurement of HIV/SIV reservoirs |
| A31. Host cellular latency |
| A32. Targeting and eradication of reservoirs |
| COVID 19 |
| A33. Basic science, pathogenesis, virology, immunology, inflammation |
| A34. Covid-19 Vaccine |
| A35. COVID-19 Molecular testing and algorithm |
| A36. COVID-19 testing RTD and Ag testing |
| A37. COVID-19 genetic diversity |
Description: This track will encompass all aspects of fundamental HIV biology and the host response to HIV. Areas of focus will include HIV infection and replication, transmission, genetics, evolution, structure and function, pathogenesis, adaptive and innate immune responses to HIV, genetic susceptibility to HIV, interaction of micronutrients, co -infection and progress in animal models. Pre-clinical vaccine, microbicide, and drug development will be important themes of this track.
Abstract Categories
| Clinical course of HIV infection and disease |
| B1. Natural history of HIV Disease including markers of HIV Disease progression |
| B2. Pre-ART Patient Care: Opportunities and Challenges |
| B3. Morbidity and mortality/life expectancy during ART |
| B4. Acute and early HIV infection, meeting the new targets (95-95-95) |
| Diagnosis and management of co-infections/co-morbidities |
| B5. Co-infections (TB, Hepatitis, STIs, Cryptococcus, bacterial diseases, leishmaniosis, Malaria and others) |
| B6. Prophylaxis against common opportunistic infections (CPT, IPT, antifungal) |
| B7. immunization in HIV infected people |
| B8. Diagnosis and management of Hepatitis B/C |
| B9. Tools for diagnosis and management of infections: point of care |
| B10. Diagnosis and management of STIs |
| B11. Syphilis, HPV and others |
| HIV and NCDS |
| B12. Diabetes, cardiovascular, renal diseases, bone mineral diseases, HIV and neurocognitive disorders) |
| B13. HIV and malignancies |
| B14. HIV, Ageing and Fragility |
| Antiretroviral therapy |
| B15. First line therapy (when to start, what to start with, durability) Differentiated HIV Care |
| B16. ART monitoring strategies |
| B17. Treatment failure: drug resistance, second line therapy and salvage therapy |
| B18. Adherence and retention |
| B19. Antiretroviral therapy in children |
| B20. Antiretroviral therapy in adolescents |
| B21. Antiretroviral therapy and PMTCT in pregnant women |
| B22 Antiretroviral therapy in elder populations |
| B23. Adverse effects of antiretroviral therapy including immune reconstitution syndrome be sure Track C integrate this (quality of life…) |
| B24. HIV-2, HIV-1+2 infections |
| B25 Management of HIV infection in Key Populations |
| B26. Cost effectiveness of ART |
| B27. Antiretroviral therapy to prevent HIV-Transmission |
| B28 ART maintenance simplification |
| Palliative care and nutrition |
| B29. Pain management and end of life care |
| B30. Clinical nutritional care in HIV infection |
| B31. Home and community based care and support |
| B32. Other Strategies and Therapies (traditional medicine, spiritual care) |
| Clinical guidelines, tools and algorithms |
| B33. Country adaptation of global HIV diagnosis and treatment guidelines |
| B34. Diagnosis and monitoring tools |
| COVID 19 |
| B35. Clinical science, testing (RT –PCR and serologic) |
| B36. COVID 19 Impact on HIV related services |
| B37. Innovation in Service delivery approaches |
Description: This track will focus on HIV and AIDS prevention research and issues related to the design, implementation and evaluation of prevention programs to reach the SDG. It will include examination of Research, methodological and programmatic advances in the continuum of prevention, particularly best practices in HIV prevention for vulnerable populations in resource-limited settings. Strategies to put HIV prevention research into practice, efforts to promote preparedness for bio-medical prevention technologies, and research on new prevention approaches including microbicides, vaccines, pre- and post-exposure prophylaxis, circumcision and other methods will be presented. This Track will also address co-morbidities (Hepatitis, Tuberculosis, and STI’s, communicable end emerging diseases) and emerging.
Abstract Categories
| Basic HIV Epidemiology |
| C1. Natural history of HIV |
| C2. HIV prevalence and incidence trends, morbidity and mortality trends |
| C3. Epidemiology in general population, risk factors for acquisition of HIV, including sero discordant couples |
| C4. Risk factors for acquisition of HIV, geographic heterogeneity and contextual |
| C5. Epidemiology of HIV in the aged (50+) |
| C6. Epidemiology of HIV in youth, adolescents and children |
| Epidemiology of HIV co‐morbidity and emerging diseases |
| C7. HIV and other sexually transmitted infections (STI) |
| C8. HIV and Tuberculosis co‐infection |
| C9. HIV and Malaria co‐infection |
| C10. HIV and Viral hepatitis co-infection |
| C11. HIV and non‐communicable diseases (cardiovascular risk, metabolic diseases, mental health, reproductive health, etc.) |
| C12. HPV infections and cancers in people living with HIV |
| C13. HIV infection in Africa and cancers associated with human papillomavirus (anus; cervix; throat), other associated cancers |
| C14. HIV, Opportunistic Infections (OI) and the epidemiology of emerging diseases |
| C15. Quality of life of people living with HIV |
| Social Epidemiology of HIV |
| C16. Sexual behavior, vulnerability and Most at Risk Populations (MARPS)including adolescent girls and young women |
| C17. Socio‐cultural and economic determinants of HIV |
| C18. Relapse of risky behaviors with the advent of ART |
| C19. Gender based violence and HIV transmission |
| HIV/AIDS Surveillance and Monitoring and Evaluation |
| C20. Modeling HIV epidemic in the advent of ART, where does M and E fit? |
| C21. HIV and AIDS Surveillance:Routine,Sentinel,Second generation and HIV phylogenetics |
| C22. Surveillance of opportunistic infections |
| C23. Surrogate markers: What remains of the measurement of CD4 T lymphocytes in a situation of accessibility of the viral load? |
| Surveillance of HIV Drug resistance |
| C24. Population‐based HIV sero epidemiologic studies, and measuring new HIV infections, including in children |
| C25. HIV reservoir: "deep" residual infectivity in HIV reservoirs in people correctly treated according to the algorithms proposed by the WHO |
| Methodological Issues and Capacity‐Building in Epidemiological and Prevention Research |
| C26. Novel Research, Ethical and human rights issues in epidemiological and prevention research |
| C27. Measuring and modelling the impact of prevention and treatment interventions on the HIV epidemic at the population level. |
| C28. Methods aimed at measuring the impact of the HIV epidemic, recent HIV infections and HIV incidence |
| C29. Surveillance systems and methods including geographical information system |
| C30. Estimation of the size of KP |
| HIV/AIDS Prevention Programmes |
| C31. Triple Elimination of Prevention of Mother to Child Transmission of HIV, Hepatitis B and syphilis |
| C32. Prevention programmes in institutional and community settings |
| C33. Prevention programmes for immigrants, mobile and displaced populations |
| C34. Integrated prevention for and with PLHIV, and key populations |
| C35. Integrated HIV prevention for adolescents and young people |
| C36. Therapeutic and psychosocial care for adolescents and young adults born to infected mothers; |
| C37. HIV Prevention technologies |
| C38. New approaches for HIV prevention |
| C39. Integrating HIV prevention into reproductive health, care, support and treatment programmes |
| C40. HIV Testing and diagnosis strategies |
| Diversified prevention tools |
| C41. PeP |
| C42. PrEP |
| C43. Microbicides |
| C44. Ehealth |
| C45. VMMC |
| COVID 19 |
| C46. Epidemiology, transmission dynamics, prevention, vaccines |
| C47. HIV Infection and COVID-19 |
| C48. Impact of COVID-19 on HIV response |
Description: This track aims to highlight new knowledge and address gaps in the translation of behavioral and social science evidence into practice, and to contribute to the building of theory and understanding in HIV-related social science. The track also aims to promote understanding of the individual and social determinants of HIV-related risk, vulnerability and impact, to inform development of effective and sustainable HIV responses that are based on human dignity and individual entitlements. This track will feature research, analysis and evaluation on psychosocial factors that shape individual attitudes, experiences, and behaviors; social and structural factors that shape vulnerability and risk; social and cultural norms that underlie individual risk and community vulnerability; programmes that promote acceptation of human diversity and fast track access to HIV and STI prevention, treatment, care and support; social and structural factors that shape vulnerability; and methods and outcomes of individual and community engagement, leadership, empowerment, and self-determination. In addition, this track will examine evidence underpinning HIV related stigma, discrimination and exclusion, lessons emerging from the practice of restoring dignity and coping capacities of those affected.
Abstract Categories
Human rights, law and ethics
| D1. Laws, protection and empowerment of PLHIV and vulnerable populations |
| D2. Human right, Protections and HIV services for Key and vulnerable populations |
| D3. Human rights, ethics and use of antiretroviral drugs for treatment and prevention |
| D4. Children’s rights, protections and HIV |
| D5. Human Rights, Sexual rights and access to citizenship |
| D6. Human rights, Ethics HIV testing, policy and practice |
| D7. Human rights, culture religion, social, behavior, culture and harm reduction |
| D8. Ethics, law and research |
| D9. Clinical services, public health policy and programmes |
| D10. Ethics, human right, access to medicines for prevention, treatment and care |
| Stigma, Discrimination and the Legal Environment |
| D11. Experience and impacts of HIV and TB related stigma |
| D12. Intersecting stigmas, marginalized identities, Homophobia and transphobia |
| D13. Racism, ethnicity-based social exclusion and HIV control |
| D14. Stigma, discrimination, key and vulnerable populations affected by HIV |
| D15. Stigma, social attitudes, media and public debate |
| D16. Punitive laws, enforcement and HIV risk |
| SEX, SEXUALITY, GENDER AND MEDIA REPORTING IN HIV |
| D17. Gender equality, power dynamics and gender equity: Addressing a feminized epidemic |
| D18. Sexualities and sexual cultures |
| D19. Adolescents, young people, and HIV |
| D20. same – sex- attracted, bisexual and queer people |
| D21. Feminity, masculinity and transgender issues in HIV |
| D22. Relationships, partnership, concurrency and sexual networks |
| D23. New prevention technologies and Family-centered approach to HIV care and support |
| D24. HIV Co-morbidities |
| Policies, Programs and HIV response |
| D25. Policy, politics and HIV management |
| D26. Law enforcement and vulnerable populations |
| D27. Harassment and Discrimination |
| D28. Harm reduction policies and politics |
| D29. Access to HIV management |
| D30. Health and HIV Policy development, implementation and evaluation |
| D31. Policies for HIV prevention, diagnosis, treatment, care, protection and support |
| D32. Policies and socio-economic determinants of vulnerability |
| D33. HIV policies, the workplace, and educational institutions |
| D34. HIV policies and intellectual property, treatment access and TRIPS |
| D35. Policy M&E, analysis, impact and indicators of policy effectiveness |
| D36. Evidence–informed advocacy for policy formulation and review |
| Social theories and knowledge production |
| D37. HIV prevention theories and approaches |
| D38. Social, cultural and behavioral science collaboration |
| D39. Methods in social and behaviour surveys |
| Communication, mass media and popular education |
| D40. Communication strategies on HIV and AIDS |
| D41. The media and HIV and AIDS |
| D42. Digital media, social networking and HIV prevention, treatment, care and support |
| D43. HIV, media, culture and religion |
| D44. Media and policy making |
| D45. Inter- organizational communication and knowledge transfer |
| D46. Intergenerational communication and HIV |
| Socio-cultural determinants of HIV |
| D47. Family structures, kinship and social security networks among key and vulnerable populations |
| D48. Harmful traditional practices and HIV |
| D49. Youth, globalization and HIV |
| D50. Sex work, the global recession and HIV |
| D51. Traditional and complementary approaches in the response to HIV |
| STRUCTURAL DETERMINANTS OF HIV |
| D52. Poverty, social and socio-economic structures and HIV |
| D53. Fertility, family planning, Reproductive rights, health and HIV |
| D54. Family-centered approach to HIV care and support |
| D55. Conceptualizing social and structural factors and their impacts |
| D56. Poverty, wealth. Income inequalities and HIV |
| D57. Dynamics of social status and power |
| D58. Gender, age, ethnicity, disability and HIV |
| D59. Economic transitions, socio-cultural changes and HIV risk |
| D60. Social dynamics, intergenerational differences and HIV |
| D61. Migrants, migration and population dislocation |
| D62. Fertility, family planning, reproductive health services and HIV |
| D63. Violence, conflict and HIV |
| D64. Humanitarian disasters and HIV |
| D65. Gender based violence and HIV |
| D66. Prisons, closed settings and HIV |
| COVID 19 |
| D67. Public Health responses including physical distancing and community level effort, programme policies, lifting restrictions, modelling. |
| D68. Intersections between Covid19 and HIV |
| D69. Impact of Covid-19 on HIV Mental Health |
| D70. Innovative approaches by communities to respond to human rights violations in the context of HIV |
| D71. Innovative approaches by communities to respond to HIV in a context of COVID 19 |
Description: This track will aim to provide new insights into the status of the health systems and its capacity and challenges to expanding treatment and prevention in resource-limited settings. At the same time, issues related to health economics, integration of health programs, country ownership of national health and HIV programs, and advancement of a comprehensive and integrated approach to health and rights will be discussed. This Track must show the need for a holistic vision of the fight against the disease by the effective strengthening of health systems. The verticalization of the fight is not a proper and appropriate response in a context where we have recurrent epidemics.
Abstract Categories
| HIV and health system strengthening |
| E1. AIDS investments for health system strengthening |
| E2. Innovative responses to resource needs for health system strengthening |
| E3. Procurement and supply chain management |
| E4. Community systems strengthening for health care delivery |
| E5. Public health systems and the delivery of HIV care at scale |
| Management for health care delivery |
| E6. Gender responsive HIV programming |
| E7. Integrated HIV service delivery services with non-health response programs |
| E8. Decentralization, differentiated care and task-shifting |
| SHARED RESPONSIBILITY, GLOBAL SOLIDARITY AND THE SDGS |
| E9. Governance – peer review and accountability mechanisms |
| E10. Sustainable financing options and financial tracking |
| E11. Accelerated access to medicines, vaccines, and diagnostics |
| E12. Capacity strengthening for HIV domestic program funding. |
| Health economics |
| E13. Building country-level capacity for quality improvement |
| E14. Evaluation of integrated models of health service delivery |
| E15. Health access financing models for HIV service delivery |
| Partnership in HIV |
| E16. Private-public partnership and HIV care delivery |
| E17. Innovative partnership models |
| Innovation and best practices |
| E18.Interventions for increase uptake of and retention in HIV services |
| E19. Public-private partnerships |
| E20. Technologies for HIV care delivery |
| COVID 19 |
| E21. Social, Economic, Political, Human right impact of the pandemic and the response. |
| E22. Integrated HIV and COVID 19 care |